Literature DB >> 21523553

A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR.

Ting Ran1, Tao Lu, Haoliang Yuan, Haichun Liu, Jian Wang, Weiwei Zhang, Ying Leng, Guowu Lin, Shulin Zhuang, Yadong Chen.   

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in the regulation of cellular growth, survival and proliferation. mTOR and PI3K have attracted particular attention as cancer targets. These kinases belong to the phosphatidylinositol-3-kinase-related kinase (PIKK) family and therefore have considerable homology in their active sites. To accelerate the discovery of inhibitors with selective activity against mTOR and PI3K as cancer targets, in this work, a homology model of mTOR was developed to identify the structural divergence in the active sites between mTOR and PI3Kα. Furthermore, two highly predictive comparative molecular similarity index analyses (CoMSIA) models were built based on 304 selective inhibitors docked into mTOR and PI3Kα, respectively (mTOR: q(2) = 0.658, r(pre)(2) = 0.839; PI3Kα: q(2) = 0.540, r(pre)(2) = 0.719). The results showed that steric and electrostatic fields have an important influence on selectivity towards mTOR and PI3Kα-a finding consistent with the structural divergence between the active sites. The findings may be helpful in investigating selective mTOR/PI3Kα inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523553     DOI: 10.1007/s00894-011-1034-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  39 in total

Review 1.  Class I phosphoinositide 3-kinases.

Authors:  Karen E Anderson; Shaun P Jackson
Journal:  Int J Biochem Cell Biol       Date:  2003-07       Impact factor: 5.085

2.  Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.

Authors:  Timothy P Heffron; Megan Berry; Georgette Castanedo; Christine Chang; Irina Chuckowree; Jennafer Dotson; Adrian Folkes; Janet Gunzner; John D Lesnick; Cristina Lewis; Simon Mathieu; Jim Nonomiya; Alan Olivero; Jodie Pang; David Peterson; Laurent Salphati; Deepak Sampath; Steve Sideris; Daniel P Sutherlin; Vickie Tsui; Nan Chi Wan; Shumei Wang; Susan Wong; Bing-Yan Zhu
Journal:  Bioorg Med Chem Lett       Date:  2010-03-12       Impact factor: 2.823

3.  2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.

Authors:  Jeroen C Verheijen; David J Richard; Kevin Curran; Joshua Kaplan; Ker Yu; Arie Zask
Journal:  Bioorg Med Chem Lett       Date:  2010-02-11       Impact factor: 2.823

Review 4.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

Review 5.  Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Authors:  James J Gibbons; Robert T Abraham; Ker Yu
Journal:  Semin Oncol       Date:  2009-12       Impact factor: 4.929

6.  Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

Authors:  Christoph M Dehnhardt; Aranapakam M Venkatesan; Efren Delos Santos; Zecheng Chen; Osvaldo Santos; Semiramis Ayral-Kaloustian; Natasja Brooijmans; Robert Mallon; Irwin Hollander; Larry Feldberg; Judy Lucas; Inder Chaudhary; Ker Yu; Jay Gibbons; Robert Abraham; Tarek S Mansour
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

7.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Authors:  Katsutoshi Oda; Jennifer Okada; Luika Timmerman; Pablo Rodriguez-Viciana; David Stokoe; Keiko Shoji; Yuji Taketani; Hiroyuki Kuramoto; Zachary A Knight; Kevan M Shokat; Frank McCormick
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

Authors:  Arie Zask; Jeroen C Verheijen; Kevin Curran; Joshua Kaplan; David J Richard; Pawel Nowak; David J Malwitz; Natasja Brooijmans; Joel Bard; Kristine Svenson; Judy Lucas; Lourdes Toral-Barza; Wei-Guo Zhang; Irwin Hollander; James J Gibbons; Robert T Abraham; Semiramis Ayral-Kaloustian; Tarek S Mansour; Ker Yu
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

9.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Authors:  Ker Yu; Lourdes Toral-Barza; Celine Shi; Wei-Guo Zhang; Judy Lucas; Boris Shor; Jamie Kim; Jeroen Verheijen; Kevin Curran; David J Malwitz; Derek C Cole; John Ellingboe; Semiramis Ayral-Kaloustian; Tarek S Mansour; James J Gibbons; Robert T Abraham; Pawel Nowak; Arie Zask
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

Review 10.  Emerging common themes in regulation of PIKKs and PI3Ks.

Authors:  Harri Lempiäinen; Thanos D Halazonetis
Journal:  EMBO J       Date:  2009-09-24       Impact factor: 11.598

View more
  4 in total

1.  Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.

Authors:  Qi Shi; Thomas M Kaiser; Zackery W Dentmon; Mariangela Ceruso; Daniela Vullo; Claudiu T Supuran; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

2.  Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma.

Authors:  Felipe Ades; Otto Metzger-Filho
Journal:  Dermatol Res Pract       Date:  2011-12-15

3.  Determination and validation of mTOR kinase-domain 3D structure by homology modeling.

Authors:  Wiame Lakhlili; Gwénaël Chevé; Abdelaziz Yasri; Azeddine Ibrahimi
Journal:  Onco Targets Ther       Date:  2015-07-30       Impact factor: 4.147

4.  Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors.

Authors:  Xiangcong Wang; Moxuan Zhang; Ranran Zhu; Zhongshan Wu; Fanhong Wu; Zhonghua Wang; Yanyan Yu
Journal:  Molecules       Date:  2022-01-08       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.